Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: Comparison with [11C]PIB

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 4, 2014, Pages 745-754

  Ito, Hiroshi ^a   Shinotoh, Hitoshi ^a   Shimada, Hitoshi ^a   Miyoshi, Michie ^a   Yanai, Kazuhiko ^b   Okamura, Nobuyuki ^b   Takano, Harumasa ^a   Takahashi, Hidehiko ^a   Arakawa, Ryosuke ^a   Kodaka, Fumitoshi ^a   Ono, Maiko ^a   Eguchi, Yoko ^a   Higuchi, Makoto ^a   Fukumura, Toshimitsu ^a   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer; Amyloid; FACT; PET; PIB

Indexed keywords

2 [[2 [2 [2 (DIMETHYLAMINO) 1,3 THIAZOL 5YL]VINY] 1,3 BENZOXAZOL 6 YL]OXY] 3 FLUOROPROPAN 1 OL F 18; AMYLOID; BENZOXAZOLE DERIVATIVE; PITTSBURGH COMPOUND B; TRACER; UNCLASSIFIED DRUG; 2-((2-(2-(2-(DIMETHYLAMINO)-1,3-THIAZOL-5-YL)VINYL)-1,3-BENZOXAZOL-6-YL)OXY)-3-FLUOROPROPAN-1-OL; BENZOTHIAZOLE DERIVATIVE; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE; RADIOPHARMACEUTICAL AGENT; THIAZOLE DERIVATIVE;

AGED; ARTICLE; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; SENILE PLAQUE; TEMPORAL CORTEX; VERY ELDERLY; WHITE MATTER; ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN; CASE CONTROL STUDY; COMPARATIVE STUDY; DIAGNOSTIC USE; EVALUATION STUDY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BENZOTHIAZOLES; BENZOXAZOLES; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES; TISSUE DISTRIBUTION;

EID: 84897029321     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2620-7     Document Type: Article

References (34)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
2. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5.
3. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-54. (Pubitemid 36702542)
4. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19. (Pubitemid 38269583)
5. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2- naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001;21:RC189.
6. Ono M, Wilson A, Nobrega J, Westaway D, Verhoeff P, Zhuang ZP, et al. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 2003;30:565-71. (Pubitemid 37289318)
7. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007;48:553-61. (Pubitemid 47571409)
8. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
9. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 2009;50:1887-94.
10. Nyberg S, Jönhagen ME, Cselényi Z, Halldin C, Julin P, Olsson H, et al. Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184. Eur J Nucl Med Mol Imaging 2009;36:1859-63.
11. Cselényi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med 2012;53:415-24.
12. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-17. (Pubitemid 41208641)
13. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-66. (Pubitemid 44684508)
14. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging β-amyloid burden in aging and dementia. Neurology 2007;68:1718-25. (Pubitemid 46763260)
15. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Aâ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999;158:328-37. (Pubitemid 29382824)
16. Masliah E, Terry RD, Mallory M, Alford M, Hansen LA. Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am J Pathol 1990;137:1293-7.
17. Price JL. Diagnostic criteria for Alzheimer's disease. Neurobiol Aging 1997;18:S67-70. (Pubitemid 27454699)
18. Furumoto S, Okamura N, Furukawa K, Tashiro M, Ishikawa Y, Sugi K, et al. A 18F-labeled BF-227 derivative as a potential radioligand for imaging dense amyloid plaques by positron emission tomography. Mol Imaging Biol 2013;15:497-506.
19. Shidahara M, Tashiro M, Okamura N, Furumoto S, Furukawa K, Watanuki S, et al. Evaluation of the biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe [18F]FACT in humans. EJNMMI Res 2013;3:32.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44. (Pubitemid 14076461)
21. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4. (Pubitemid 23346995)
22. Folstein MF, Folstein SE, McHugh PR. " Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
23. Matsumoto K, Kitamura K, Mizuta T, Tanaka K, Yamamoto S, Sakamoto S, et al. Performance characteristics of a new 3- dimensional continuous-emission and spiral-transmission highsensitivity and high-resolution PET camera evaluated with the NEMA NU 2-2001 standard. J Nucl Med 2006;47:83-90. (Pubitemid 46768516)
24. Ishikawa A, Kitamura K, Mizuta T, Tanaka K, Amano M, Inoue Y, et al. Implementation of on-the-fly scatter correction using dual energy window method in continuous 3D whole body PETscanning. IEEE Nucl Sci Symp Conf Rec 2005;5:2497-500. (Pubitemid 46172253)
25. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528-47. (Pubitemid 41541962)
26. Ito H, Hietala J, Blomqvist G, Halldin C, Farde L. Comparison of the transient equilibriumand continuous infusionmethod for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab 1998;18:941-50.
27. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowiak RS. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 1990;10:458-66. (Pubitemid 20209192)
28. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 2000;11:805-21.
29. Müller-Gärtner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571-83.
30. Ito H, Inoue K, Goto R, Kinomura S, Taki Y, Okada K, et al. Database of normal human cerebral blood flow measured by SPECT: I. Comparison between I-123-IMP, Tc-99m-HMPAO, and Tc-99m-ECD as referred with O-15 labeled water PET and voxelbased morphometry. Ann Nucl Med 2006;20:131-8.
31. Higuchi M, Iwata N, Matsuba Y, Sato K, Sasamoto K, Saido TC. 19F and 1HMRI detection of amyloid beta plaques in vivo. Nat Neurosci 2005;8:527-33. (Pubitemid 41007572)
32. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-45. (Pubitemid 351806448)
33. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Harigaya Y. Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol 1988;77:113-9. (Pubitemid 19015547)
34. Jack Jr CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-80. (Pubitemid 351294719)